Q3 EPS Forecast for Solid Biosciences Increased by Analyst

Key Points

• Leerink Partners raised their Q3 2025 earnings per share estimate for Solid Biosciences to ($0.43), an improvement from a prior estimate of ($0.60).
• Solid Biosciences reported a quarterly EPS of ($0.42), exceeding analysts' expectations of ($0.51).
• A majority of market analysts have a buy rating on Solid Biosciences, with an average price target of $15.00 per share.

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Analysts at Leerink Partnrs boosted their Q3 2025 EPS estimates for shares of Solid Biosciences in a research note issued to investors on Wednesday, August 13th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.43) per share for the quarter, up from their prior forecast of ($0.60). The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for Solid Biosciences' Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.85) EPS and FY2026 earnings at ($1.92) EPS.

SLDB has been the subject of several other reports. JPMorgan Chase & Co. cut their target price on shares of Solid Biosciences from $15.00 to $13.00 and set an "overweight" rating for the company in a research note on Thursday, August 14th. Wall Street Zen upgraded shares of Solid Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Barclays decreased their target price on Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating on the stock in a research report on Friday, May 16th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Solid Biosciences in a report on Tuesday, June 17th. Finally, Piper Sandler decreased their price objective on Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating on the stock in a report on Friday, May 16th. Two equities research analysts have rated the stock with a Strong Buy rating and ten have issued a Buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $15.00.

Solid Biosciences Stock Up 0.2%

Shares of SLDB stock traded up $0.01 during trading hours on Monday, reaching $5.67. 412,357 shares of the company's stock were exchanged, compared to its average volume of 1,912,999. Solid Biosciences has a fifty-two week low of $2.41 and a fifty-two week high of $10.11. The stock has a market capitalization of $441.52 million, a P/E ratio of -2.03 and a beta of 2.44. The business has a fifty day moving average price of $5.69 and a 200-day moving average price of $4.48.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09.

Hedge Funds Weigh In On Solid Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SLDB. Adage Capital Partners GP L.L.C. boosted its stake in Solid Biosciences by 285.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 6,729,484 shares of the company's stock worth $24,899,000 after purchasing an additional 4,981,400 shares in the last quarter. Bain Capital Life Sciences Investors LLC raised its holdings in shares of Solid Biosciences by 96.1% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 7,911,669 shares of the company's stock valued at $29,273,000 after buying an additional 3,877,087 shares during the last quarter. Siren L.L.C. lifted its position in Solid Biosciences by 97.8% during the 1st quarter. Siren L.L.C. now owns 7,415,905 shares of the company's stock worth $27,439,000 after buying an additional 3,666,864 shares in the last quarter. MPM Bioimpact LLC acquired a new position in Solid Biosciences during the 1st quarter worth about $6,077,000. Finally, Nantahala Capital Management LLC raised its stake in shares of Solid Biosciences by 505.4% in the second quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company's stock worth $8,295,000 after acquiring an additional 1,421,968 shares during the last quarter. 81.46% of the stock is currently owned by institutional investors and hedge funds.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.